A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-21. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Ethylene glycol is first metabolized to glycolaldehyde by alcohol dehydrogenase. Glycolaldehyde then undergoes further oxidation to glycolate, glyoxylate, and oxalate. Glycolate and oxalate are the primary toxins responsible for the metabolic acidosis, and for the renal damage, seen in ethylene glycol poisoning. Methanol is first metabolized to formaldehyde by alcohol dehydrogenase. Formaldehyde then undergoes further oxidation, via formaldehyde dehydrogenase, to become formic acid. Formic acid is the primary toxin responsible for the metabolic acidosis, and for the visual disturbances, associated with methanol poisoning. By competitively inhibiting the first enzyme, alcohol dehydrogenase, in the metabolism of ethylene glycol and methanol, fomepizole slows the production of the toxic metabolites. The slower rate of metabolite production allows the liver to process and excrete the metabolites as they are produced, limiting the accumulation in tissues such as the kidney and eye. As a result, much of the organ damage is avoided.
Diseases of the endocrine glands are common, including conditions such as diabetes mellitus, thyroid disease, and obesity. Endocrine disease is characterized by irregulated hormone release (a productive pituitary adenoma), inappropriate response to signalling (hypothyroidism), lack of a gland (diabetes mellitus type 1, diminished erythropoiesis in chronic kidney failure), or structural enlargement in a critical site such as the thyroid (toxic multinodular goitre). Hypofunction of endocrine glands can occur as a result of the loss of reserve, hyposecretion, agenesis, atrophy, or active destruction. Hyperfunction can occur as a result of hypersecretion, loss of suppression, hyperplastic, or neoplastic change, or hyperstimulation. Endocrinopathies are classified as primary, secondary, or tertiary. Primary endocrine disease inhibits the action of downstream glands. Secondary endocrine disease is indicative of a problem with the pituitary gland. Tertiary endocrine disease is associated with dysfunction of the hypothalamus and its releasing hormones. As the thyroid, and hormones have been implicated in signaling distant tissues to proliferate, for example, the estrogen receptor has been shown to be involved in certain breast cancers. Endocrine, paracrine, and autocrine signaling have all been implicated in proliferation, one of the required steps of oncogenesis. Other common diseases that result from endocrine dysfunction include Addison's disease, Cushing's disease and Grave's disease.
Systemic diseases may be associated with the development of periodontitis. It is thought that the host immune response to plaque is altered by the systemic condition. Hematological disorders associated with periodontitis include acquired neutropenia, leukemias and others. Genetic disorders potentially associated include familial and cyclic neutropenia, Down syndrome, leukocyte adhesion deficiency syndromes, Papillon–Lefèvre syndrome, Chédiak–Higashi syndrome, histiocytosis syndromes, glycogen storage disease, infantile genetic agranulocytosis, Cohen syndrome, Ehlers–Danlos syndrome (Types IV and VIII), hypophosphatasia, and others.
== Industrial uses == Penicillium digitatum is used as a biological tool during the commercial production of latex agglutination kits. Latex agglutination detects Aspergillus and Penicillium species in foods by attaching antibodies specific for the extracellular polysaccharide of P. digitatum to 0.8 μm latex beads. This method has been successful in detecting contamination of grains and processed foods at a limit of detection of 5–10 ng/mL of antigen. In comparison to other detection assays, the latex agglutination assay exceeds the detection limit of the Enzyme-linked immunosorbent assay (ELISA) and is as effective in detecting Aspergillus and Pencillium species as the ergosterol production assay. However, the latter displays an increased ability to detect Fusarium species, when compared to the latex agglutination assay.
Sources: en.wikipedia.org
== Techniques == Hydroponic systems typically fall into two irrigation categories: sub-irrigation systems, where nutrient solution is supplied from below and roots absorb moisture upward (e.g., deep water culture, ebb-and-flow), and top-irrigation systems, where nutrient solution is applied from above through drip emitters or sprayers (e.g., nutrient film technique, aeroponics). Hydroponic techniques aim to simultaneously optimize the water, nutrient and oxygen supply to the plant roots. For all techniques, most hydroponic reservoirs are now built of plastic, but other materials have been used, including concrete, glass, metal, vegetable solids, and wood. The containers should exclude light to prevent algae and fungal growth in the hydroponic medium.
== Labeling == The actual leather content of bonded leather varies depending on the manufacturer and the quality level. There is some debate and controversy over the ethics of using the term "bonded leather" to describe an upholstery product, which is actually a reconstituted leather, specifically in the home furnishings industry. A Leather Research Laboratory commented calling a product "bonded leather" is "deceptive because it does not represent its true nature. It's a vinyl, or a polyurethane laminate or a composite, but it's not leather". In 2011 the European Committee for Standardization published EN 15987:2011 'Leather - Terminology - Key definitions for the leather trade' to stop confusion about bonded leather, according to which the minimum amount of 50% in weight of dry leather is needed to use the term "bonded leather". The US Federal Trade Commission recommends giving a percentage of leather included. The Federal Trade Commission has said that "The guidelines caution against misrepresentations about the leather content in products containing ground, reconstituted, or bonded leather, and state that such products, when they appear to be made of leather, should be accompanied by a disclosure as to the percentage of leather or other fiber content. The guidelines also state that these disclosures should be included in any product advertising that might otherwise mislead consumers as to the composition of the product."
==== MeSH D12.776.556.579.374 – nonheme iron proteins ==== MeSH D12.776.556.579.374.187 – hemerythrin MeSH D12.776.556.579.374.281 – inositol oxygenase MeSH D12.776.556.579.374.375 – iron-sulfur proteins MeSH D12.776.556.579.374.375.025 – adrenodoxin MeSH D12.776.556.579.374.375.150 – ferredoxin-nitrite reductase MeSH D12.776.556.579.374.375.275 – ferredoxins MeSH D12.776.556.579.374.375.275.450 – molybdoferredoxin MeSH D12.776.556.579.374.375.275.725 – rubredoxins MeSH D12.776.556.579.374.375.637 – iron regulatory protein 1 MeSH D12.776.556.579.374.375.818 – iron regulatory protein 2 MeSH D12.776.556.579.374.375.863 – electron transport complex i MeSH D12.776.556.579.374.375.863.500 – nadh dehydrogenase MeSH D12.776.556.579.374.375.909 – electron transport complex ii MeSH D12.776.556.579.374.375.909.500 – succinate dehydrogenase MeSH D12.776.556.579.374.375.954 – electron transport complex iii MeSH D12.776.556.579.374.375.977 – nitrate reductase (nad(p)h) MeSH D12.776.556.579.374.375.988 – nitrate reductase (nadph) MeSH D12.776.556.579.374.450 – lipoxygenase MeSH D12.776.556.579.374.450.025 – arachidonate lipoxygenases MeSH D12.776.556.579.374.450.025.020 – arachidonate 5-lipoxygenase MeSH D12.776.556.579.374.450.025.025 – arachidonate 12-lipoxygenase MeSH D12.776.556.579.374.450.025.030 – arachidonate 15-lipoxygenase MeSH D12.776.556.579.374.687 – retinal dehydrogenase MeSH D12.776.556.579.374.925 – tyrosine 3-monooxygenase
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.